Drugs / CoVepiT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04885361 | May → Sep 2021 | COVID-19 | OSE Immunotherapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoVepiT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04885361 ↗ |
| Known as | OSE13E | “CoVepiT (OSE13E)” NCT04885361 ↗ |
| Modality | Vaccine | “peptide-based vaccine” NCT04885361 ↗ |
| Route | Subcutaneous | “will be administered subcutaneously” NCT04885361 ↗ |